SciELO - Scientific Electronic Library Online

vol.61 número2Estudio prospectivo de intervención sobre comorbilidades, interacciones farmacológicas y su manejo en pacientes con cáncerDesarrollo tecnológico del inyectable heparina sódica 5.000 UI/mL en solución índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Ars Pharmaceutica (Internet)

versión On-line ISSN 2340-9894


BARROS, Gabriel Romero Melo do Rêgo et al. Financial impact of antibiotic therapy face to bacterial multiresistance in emergency hospital in Pernambuco, Brazil. Ars Pharm [online]. 2020, vol.61, n.2, pp.121-126.  Epub 20-Jul-2020. ISSN 2340-9894.


The objective of this article was to analyze the financial costs of antibiotic therapy against bacterial resistance in a public hospital of high complexity located in the Agreste region of Pernambuco.


It was performed a descriptive, retrospective and cross-sectional study based on data collected from Hospital Infection Control Commission (CCIH) and the Pharmaceutical Supply Center (CAF) of the investigated hospital. It was obtained by a structured instrument of data collection and the period analysed was from January to December 2016.


The main clinical samples with presence of bacterial multiresistance were blood, urine and tracheal secretion, with a higher prevalence of the following bacteria: Staphylococcus aureus(23,08%), Coagulase-negative Staphylococcus(26,15%), Citrobactersp. (19,23%), Enterobactersp. (10,77%) and Pseudomonassp (7,69%). Faced to the multiresistance presented, the most common antibiotics used in the treatment were: vancomycin (21,7%), piperacillin-tazobactam (24,55%), ampicillin-sulbactam (10,4%), cefepime (18,43%) and meropenem (58,5%). The presence of resistant bacteria was a cause of increased costs in the treatment of patients. According to this study, the antibiotic therapy listed above generated a cost of R$ 83.298,83 and 49% of hospital death in 2016.


The prevention, through of policies related to the control and rational use of antimicrobials, is fundamental in the fight against hospital infections caused by multiresistant bacteria.

Palabras clave : Bacteria; Drug Resistance Microbial; Hospital Costs.

        · resumen en Español     · texto en Español     · Español ( pdf )